Clinical Case Reports (Jul 2023)
Pemigatinib treatment for intrahepatic cholangiocarcinoma with FGFR2 fusion detected by a liquid comprehensive genomic profiling test
- Shun Ishido,
- Nobuharu Tamaki,
- Kento Inada,
- Jun Itakura,
- Yuka Takahashi,
- Naoki Uchihara,
- Keito Suzuki,
- Yuki Tanaka,
- Haruka Miyamoto,
- Michiko Yamada,
- Hiroaki Matsumoto,
- Tsubasa Nobusawa,
- Taisei Keitoku,
- Kenta Takaura,
- Shohei Tanaka,
- Chiaki Maeyashiki,
- Yutaka Yasui,
- Kaoru Tsuchiya,
- Hiroyuki Nakanishi,
- Masayuki Kurosaki,
- Namiki Izumi
Affiliations
- Shun Ishido
- Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan
- Nobuharu Tamaki
- Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan
- Kento Inada
- Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan
- Jun Itakura
- Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan
- Yuka Takahashi
- Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan
- Naoki Uchihara
- Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan
- Keito Suzuki
- Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan
- Yuki Tanaka
- Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan
- Haruka Miyamoto
- Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan
- Michiko Yamada
- Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan
- Hiroaki Matsumoto
- Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan
- Tsubasa Nobusawa
- Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan
- Taisei Keitoku
- Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan
- Kenta Takaura
- Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan
- Shohei Tanaka
- Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan
- Chiaki Maeyashiki
- Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan
- Yutaka Yasui
- Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan
- Kaoru Tsuchiya
- Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan
- Hiroyuki Nakanishi
- Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan
- Masayuki Kurosaki
- Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan
- Namiki Izumi
- Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan
- DOI
- https://doi.org/10.1002/ccr3.7664
- Journal volume & issue
-
Vol. 11,
no. 7
pp. n/a – n/a
Abstract
Key Clinical Message The liquid CGP was useful for detecting FGFR2 fusion and the patient experienced typical side effects (nail disorders, hyperphosphatemia, and taste disorders) of pemigatinib that required treatment.
Keywords
- comprehensive genomic profiling
- fibroblast growth factor receptor 2
- intrahepatic cholangiocarcinoma
- pemigatinib
